Showing results (101-110 of 120) with videos related to
Sort By:
Pageof 12
Ebiomedicine|November 9, 2020
High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patientsElena Yeregui, Consuelo Viladés, Pere Domingo, et al.Atherosclerosis|April 21, 2018
Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapyEsther Rodríguez-Gallego, Josep Gómez, Pere Domingo, et al.Antiviral Research|March 28, 2017
Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recoveryIsaac Rosado-Sánchez, Inmaculada Jarrín, María M Pozo-Balado, et al.Journal of the Pediatric Infectious Diseases Society|February 2, 2023
Transient Viral Rebound in Children with Perinatally Acquired HIV-1 Induces a Unique Soluble Immunometabolic Signature Associated with Decreased CD4/CD8 RatioLaura Tarancon-Diez, Joaquim Peraire, Santiago Jiménez de Ory, et al.The Journal of Antimicrobial Chemotherapy|November 8, 2008
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohortManuel Crespo, Esteban Ribera, Ignacio Suárez-Lozano, et al.International Journal of Molecular Sciences|February 26, 2022
Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4<sup>+</sup> T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral TherapyElena Yeregui, Jenifer Masip, Consuelo Viladés, et al.Frontiers in Immunology|May 6, 2022
Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV ControlJenifer Masip, Norma Rallón, Elena Yeregui, et al.The Journal of Infectious Diseases|October 13, 2018
Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite ControlEsther Rodríguez-Gallego, Laura Tarancón-Diez, Felipe García, et al.The Journal of Antimicrobial Chemotherapy|March 22, 2008
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohortPere Domingo, Ignacio Suárez-Lozano, Ferran Torres, et al.Enfermedades Infecciosas Y Microbiologia Clinica|February 5, 2010
Characteristics and outcome of HIV infection in gypsies in the Spanish VACH CohortRamón Teira, Ignacio Suárez-Lozano, Fernando Lozano, et al.Pageof 12